Microdosing GLP-1s: what it saves you, and what it doesn't

Microdosing a GLP-1 does not save you money at a compounded seller. We checked every compounded program on our board in October 2026, and not one charges less when you take less. The rest of this page is why, and where a lower dose genuinely does cost less.

Start with what the word is.

Microdosing is not a medical term. It's a term that has been popularized on social media...

Dr Amanda Velazquez, Director of Obesity Medicine, Cedars-Sinai

That matters more than it sounds. Because there is no clinical definition, there is no agreed dose, no protocol and no way to compare one seller's version with another's. In psychedelics research, where the term came from, microdosing means a specific sub-perceptual fraction. Here it means whatever the person using the word wants it to mean, most often somewhere below the label's starting dose, or staying at a starting dose indefinitely instead of titrating up.¹

What the evidence actually says

The same source, on the substance rather than the word:¹

We don't have any evidence that low-dose, intermittent use of GLP-1s provides meaningful or sustained weight loss or broader health benefits. Even more concerning are the potential risks of inappropriate use.

Cedars-Sinai

To be fair to the idea, that is a statement about absent evidence rather than proof of absent effect, and somebody is now testing it. A study registered on ClinicalTrials.gov is running with exactly this question:³

The Primary Objective is to evaluate the effectiveness of microdosed GLP-1 receptor agonists in improving measures of health, quality of life, and longevity.

ClinicalTrials.gov, NCT07092605

The money claim, which we can actually check

We are a price tracker, so this is the part we can settle rather than opine on. The central promise of microdosing is that a smaller dose costs less. We went through the offer-level pricing of every compounded program on our board, re-checked in October 2026.

Not one of them charges less for a smaller dose. Every compounded program prices a flat monthly rate whatever you inject. Use a quarter of the vial or all of it, the bill is the same.

One thing to watch, because it fooled us on the first pass: plenty of these sellers show four different prices for the same product, which looks like dose pricing. It is not. It is the prepay term: the same vial, cheaper per month the longer you commit, with no dose attached to any of the four. You are being paid to commit, not to take less.

What about the seller that actually sells microdosing?

One partner program on our board sells microdosing as its own product with its own price: Enhance MD, whose “Microdosing Tirzepatide” is listed at 1 mg a week. When we first checked in August a second seller listed one too; by October it no longer did.

• Against its own full dose, it is cheaper. At Enhance MD the microdosing product costs less a month than the same seller’s full-dose compounded tirzepatide. That is the only place on our board where taking less costs less, and it is because it is sold as a different product, not because the price follows your dose.
• Against the market, it is not. It costs more a month than full-dose compounded tirzepatide at the cheapest seller we track, and its lowest price needs a twelve-month prepay.

Where a lower dose really does cost less

Here is the inversion, and it is the useful part of this page.

The steep dose ladders belong to the brands, which is exactly where nobody markets microdosing. Lilly publishes theirs:⁴

Available through Zepbound self-pay, Zepbound is offered as a 4-count single-dose vial (0.5mL) and a single-patient-use KwikPen (2.4mL, 0.6mL/dose) in doses of 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg, with direct-to-patient pricing of $299, $399, $499, $699, $699 and $699 respectively.

Eli Lilly, read 3 October 2026

On those list prices that is a $400 monthly spread between the starting dose and the top of the ladder, and it is the manufacturer's own published price rather than anybody's marketing. The ladder above also shows any purchase offer Lilly runs on top, and the cheapest seller price at each step. If you are paying cash for a brand and you and your prescriber conclude a lower dose holds your result, the saving is large and entirely legitimate. Nobody calls that microdosing. They call it staying on the dose that works, which is a normal clinical conversation with a real financial consequence.

The same holds when a telehealth program sells a brand. Sesame Care, on our board, prices brand Ozempic and Foundayo by dose on its own pricing page, so on those a lower dose is a lower bill there too.

So the pattern reverses cleanly. Dose changes your bill on the brands, where the word is never used. Dose changes nothing on compounded vials, where the word is used constantly.

The thing that could end this anyway

Microdosing in practice depends on compounded multi-dose vials, because you cannot meaningfully subdivide a fixed-dose branded pen. That supply is now in question.

On 30 April 2026 the FDA proposed removing the three molecules this market runs on:²

the FDA did not identify a clinical need for outsourcing facilities to compound semaglutide, tirzepatide, and liraglutide from bulk drug substances. "When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need," said FDA Commissioner Marty Makary, M.D., M.P.H.

FDA

The comment period, extended once, closed on 30 July 2026 and a final determination is pending. We are not going to predict the outcome. But if you are choosing a protocol that only exists because compounded vials exist, that is a risk worth pricing in, and it argues against building a long plan around it.

The legitimate version of this idea

Strip away the word and there is something real underneath, which is worth separating out.

• Every label already starts low. Wegovy begins at 0.25 mg, Zepbound at 2.5 mg, Foundayo at 0.8 mg, and each titrates up over weeks. Low-and-slow is not a hack; it is the approved schedule, and it exists mainly to limit nausea.
• Staying at a lower dose is a normal conversation, but not automatically an approved one. Lilly states plainly that for Zepbound, “2.5 mg is a starting dose and is not approved as a maintenance dose.”⁵ So parking there indefinitely is off-label, which does not make it wrong, but does make it your prescriber’s call rather than a self-service decision.
• Going below the starting dose is the untested part. That is the bit with no trial behind it, and it is what the quotes above are actually warning about.
• Never split a dose to stretch a supply you are struggling to afford. Price the alternatives instead. The spread between the cheapest and dearest program we track is several hundred dollars a month for the same molecule.

What we would actually check

• Ask whether your program prices by dose. On our data no compounded program does, which removes the main reason most people are asking in the first place.
• Are you paying brand cash prices? Then the ladder is steep and dose genuinely is a money question, for your prescriber and you together.
• Is anyone offering you a protocol with no published basis? Ask what it is based on. "Not a medical term" is a fair thing to quote back.
• If cost is the real driver, compare programs before you compare doses. Every route without insurance, priced.

Nothing here is dosing advice, and we do not give any: what dose you take is between you and your prescriber. What we can tell you is what each option costs, which sellers change their price when your dose changes, and which do not.